Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 40Pancreatic Neoplasms 17Breast Neoplasms 17Esophageal Neoplasms 14Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Triple Negative Breast Neoplasms 11Rectal Neoplasms 11Neoplasm Metastasis 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Head and Neck Neoplasms 7Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Nasopharyngeal Carcinoma 5Leukemia, Myeloid, Acute 5Endometrial Neoplasms 5Recurrence 4NSCLC 4Mouth Neoplasms 4Colonic Neoplasms 4Lymphoma 3Glioma 3Cholangiocarcinoma 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2

Interventions

Paclitaxel 4pembrolizumab 3Cisplatin 3Doxorubicin 2Carboplatin 2Brachytherapy 2Biopsy 2trastuzumab deruxtecan 1sacituzumab govitecan 1relugolix 1dostarlimab 1dehydroftorafur 1belzutifan 1Watchful Waiting 1Vaginal Smears 1VMBP protocol 1Ultrasound, High-Intensity Focused, Transrectal 1Transurethral Resection of Prostate 1Taxes 1Sutures 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Pregnancy Tests 1Practice Guidelines as Topic 1Platinum 1Papanicolaou Test 1Oxaliplatin 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Neoplasms × Drug Therapy × Clear all
NCT06692166 2024-11-22

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Recruiting
420 enrolled
Gynecologic

Uterine Cervical Diseases, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Uterine Diseases, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡